Dr. Grupp focuses on required preparations, recovery phase, and potential new applications of CAR T-cell therapy.

The Templeton family's $3 million gift to CHOP will support the Philadelphia Coalition for a Cure, a brain tumor initiative led by CHOP’s Center for Data-Driven Discovery in Biomedicine.

Emily Whitehead, the first pediatric patient to receive CAR T-cell therapy, and her family honor the CHOP team who saved her life with a $250,000 research grant to expand the use of the therapy for relapsed or refractory ALL.

The Neurofibromatosis Multidisciplinary Clinic allows patients with NF1 to see three or more specialists in one day, allowing for a seamless flow of appointments from morning until afternoon.

Updated results from a global clinical trial of the CAR T-cell therapy for ALL reveal that children and young adults continued to show high rates of durable, complete remission of their disease.

Charles Phillips, MD, a CHOP fellow, recounts his experience caring for a cancer patient and the many firsts it brought to the both of them.

CHOP has been at the forefront of developing cell therapy to treat ALL. Some next steps include initiating clinical trials for AML and, ultimately, making this treatment work for solid tumors.

With the majority of Hodgkin lymphoma patients surviving their disease, the focus has turned to minimizing the long-term effects of treatment while maintaining excellent cure rates.

Using the case of a 14-year-old male diagnosed with osteosarcoma, we discuss the diagnosis and treatment of bone cancer with the goal of preserving limbs and functions.

Philanthropy helped CHOP develop the first cell therapy to receive FDA approval and provide lifesaving treatments to 170 children with ALL, like Paulina.